Clinical Research Details
Title:
Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin’s Lymphoma Beyond First Complete Response BMT CTN PROTOCOL 0701
Purpose:
The primary objective of this study is to measure progression-free survival at two years after non-myeloablative HSCT with a pre-transplant conditioning regimen of fludarabine, cyclophosphamide and rituximab (FCR).
Study Number:
201808052009
Number of Patients:
65
Elgibility:
Adults = 75 with confirmed CD20+ follicle center lymphoma.
Patients must demonstrate chemosensitive or radiosensitive disease to most recent prior regimen.
Treatment:
Participants will receive chemotherapy plus rituximab followed by stem cell transplant.
Principal Investigator:
Enrollment Phone:
(708) 327-3304